UA95959C2 - Leptomycin derivatives - Google Patents

Leptomycin derivatives

Info

Publication number
UA95959C2
UA95959C2 UAA200900137A UAA200900137A UA95959C2 UA 95959 C2 UA95959 C2 UA 95959C2 UA A200900137 A UAA200900137 A UA A200900137A UA A200900137 A UAA200900137 A UA A200900137A UA 95959 C2 UA95959 C2 UA 95959C2
Authority
UA
Ukraine
Prior art keywords
leptomycin
leptomycin derivatives
derivatives
therapeutic use
conjugates
Prior art date
Application number
UAA200900137A
Other languages
English (en)
Ukrainian (uk)
Inventor
Эрве Бушар
Ален Коммерсон
Рави В. Дж. Чаре
Original Assignee
Санофи-Авентис
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37311892&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA95959(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Санофи-Авентис filed Critical Санофи-Авентис
Publication of UA95959C2 publication Critical patent/UA95959C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6863—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from stomach or intestines cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Pyrane Compounds (AREA)

Abstract

Описаны производные лептомицина, имеющие группу, такую как сульфидная или дисульфидная, которые могут соединяться со связывающимся с клеткой реагентом, таким как антитела. Описано также терапевтическое применение коньюгатов производной лептомицина; такие коньюгаты находят терапевтическое применение, поскольку они могут доставлять цитотоксичные производные лептомицина к конкретной популяции клеток направленным образом.
UAA200900137A 2006-06-09 2007-05-23 Leptomycin derivatives UA95959C2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06290948A EP1864682A1 (en) 2006-06-09 2006-06-09 Leptomycin derivatives

Publications (1)

Publication Number Publication Date
UA95959C2 true UA95959C2 (en) 2011-09-26

Family

ID=37311892

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200900137A UA95959C2 (en) 2006-06-09 2007-05-23 Leptomycin derivatives

Country Status (29)

Country Link
US (2) US7816543B2 (ru)
EP (3) EP1864682A1 (ru)
JP (1) JP5162581B2 (ru)
KR (1) KR20090018103A (ru)
CN (2) CN102731611A (ru)
AR (1) AR063668A1 (ru)
AU (1) AU2007258896B2 (ru)
BR (1) BRPI0712899A2 (ru)
CA (1) CA2654322A1 (ru)
CL (1) CL2007001648A1 (ru)
CR (1) CR10459A (ru)
EA (1) EA017345B1 (ru)
EC (1) ECSP088936A (ru)
GT (1) GT200800277A (ru)
HK (1) HK1134240A1 (ru)
HN (1) HN2008001788A (ru)
IL (1) IL195419A0 (ru)
MA (1) MA30689B1 (ru)
ME (1) MEP88208A (ru)
MX (1) MX2008015728A (ru)
MY (1) MY148231A (ru)
NO (1) NO20085127L (ru)
NZ (1) NZ572947A (ru)
SG (2) SG174067A1 (ru)
TN (1) TNSN08463A1 (ru)
TW (1) TWI411609B (ru)
UA (1) UA95959C2 (ru)
WO (1) WO2007144709A2 (ru)
ZA (1) ZA200810015B (ru)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1864682A1 (en) * 2006-06-09 2007-12-12 Sanofi-Aventis Leptomycin derivatives
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
CN101732308B (zh) * 2008-11-17 2011-11-30 中国人民解放军军事医学科学院毒物药物研究所 来普霉素b的新用途及含有它的药物组合物和产品
SG173152A1 (en) 2009-02-05 2011-08-29 Immunogen Inc Novel benzodiazepine derivatives
FR2947269B1 (fr) 2009-06-29 2013-01-18 Sanofi Aventis Nouveaux composes anticancereux
FR2949469A1 (fr) 2009-08-25 2011-03-04 Sanofi Aventis Derives anticancereux, leur preparation et leur application en therapeutique
TW201117814A (en) 2009-10-02 2011-06-01 Sanofi Aventis New maytansinoids and the use of said maytansinoids to prepare conjugates with an antibody
WO2011100403A1 (en) 2010-02-10 2011-08-18 Immunogen, Inc Cd20 antibodies and uses thereof
FR2963007B1 (fr) 2010-07-26 2013-04-05 Sanofi Aventis Derives anticancereux, leur preparation et leur application therapeutique
EP3666289A1 (en) 2011-02-15 2020-06-17 ImmunoGen, Inc. Cytotoxic benzodiazepine derivatives
AU2012385228B2 (en) 2012-07-12 2016-10-06 Hangzhou Dac Biotech Co., Ltd Conjugates of cell binding molecules with cytotoxic agents
GB201309807D0 (en) * 2013-05-31 2013-07-17 Pharma Mar Sau Antibody drug conjugates
US20150148411A1 (en) * 2013-11-25 2015-05-28 The Rockefeller University Compositions and methods for diagnosis and therapy of disorders related to alterations of myh9
CN110478495A (zh) 2014-06-30 2019-11-22 塔弗达治疗有限公司 靶向缀合物及其颗粒和制剂
MA43345A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
CN108473538B (zh) 2015-10-28 2022-01-28 塔弗达治疗有限公司 Sstr靶向缀合物及其颗粒和制剂
WO2017194568A1 (en) 2016-05-11 2017-11-16 Sanofi Treatment regimen using anti-muc1 maytansinoid immunoconjugate antibody for the treatment of tumors
US11562115B2 (en) 2017-01-04 2023-01-24 Stmicroelectronics S.R.L. Configurable accelerator framework including a stream switch having a plurality of unidirectional stream links
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
AU2018315154B2 (en) * 2017-08-09 2022-11-10 Helmholtz-Zentrum für Infektionsforschung GmbH New targeted cytotoxic ratjadone derivatives and conjugates thereof
US11531873B2 (en) 2020-06-23 2022-12-20 Stmicroelectronics S.R.L. Convolution acceleration with embedded vector decompression

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4792522A (en) 1983-12-12 1988-12-20 Bristol-Myers Company Rigolettone antitumor complex
US4625014A (en) 1984-07-10 1986-11-25 Dana-Farber Cancer Institute, Inc. Cell-delivery agent
US4771070A (en) 1984-08-21 1988-09-13 Warner-Lambert Company CL-1957A antibiotic compound
US4764368A (en) 1984-08-29 1988-08-16 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US4542225A (en) 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
ES2149768T3 (es) 1992-03-25 2000-11-16 Immunogen Inc Conjugados de agentes enlazantes de celulas derivados de cc-1065.
AU6368500A (en) * 1999-07-22 2001-02-13 University Of Medicine And Dentistry Of New Jersey Materials and processes for controlled release of thioamide moiety-containing therapeutic agents by linking to thiol-containing polymers
AU2001294511A1 (en) 2000-06-30 2002-01-08 The Regents Of The University Of California New strategy for leukemia therapy
WO2002062396A2 (en) * 2001-02-08 2002-08-15 University Of Medicine And Dentistry Of New Jersey Enhanced oral and transcompartmental delivery of therapeutic or diagnostic agents using polymer conjugates
WO2004043344A2 (en) 2002-11-07 2004-05-27 Immunogen, Inc. Anti-cd33 antibodies and method for treatment of acute myeloid leukemia using the same
EP2286844A3 (en) * 2004-06-01 2012-08-22 Genentech, Inc. Antibody-drug conjugates and methods
US7446196B2 (en) * 2004-06-03 2008-11-04 Kosan Biosciences, Incorporated Leptomycin compounds
US7541330B2 (en) * 2004-06-15 2009-06-02 Kosan Biosciences Incorporated Conjugates with reduced adverse systemic effects
WO2006135371A1 (en) * 2005-06-09 2006-12-21 Kosan Biosciences Incorporated Conjugates with reduced adverse systemic effects
EP1864682A1 (en) * 2006-06-09 2007-12-12 Sanofi-Aventis Leptomycin derivatives

Also Published As

Publication number Publication date
US7816543B2 (en) 2010-10-19
HK1134240A1 (en) 2010-04-23
GT200800277A (es) 2009-06-16
WO2007144709A3 (en) 2008-06-12
NZ572947A (en) 2011-12-22
CA2654322A1 (en) 2007-12-21
JP2009539820A (ja) 2009-11-19
ECSP088936A (es) 2009-01-30
WO2007144709A2 (en) 2007-12-21
MY148231A (en) 2013-03-29
US20110002947A1 (en) 2011-01-06
EA017345B1 (ru) 2012-11-30
ZA200810015B (en) 2010-02-24
EP2540320A1 (en) 2013-01-02
AR063668A1 (es) 2009-02-11
TW200812996A (en) 2008-03-16
TWI411609B (zh) 2013-10-11
CN101466409A (zh) 2009-06-24
EP2032172B1 (en) 2012-06-06
IL195419A0 (en) 2009-08-03
CL2007001648A1 (es) 2008-01-18
SG174066A1 (en) 2011-09-29
JP5162581B2 (ja) 2013-03-13
CN102731611A (zh) 2012-10-17
MEP88208A (en) 2011-12-20
EA200870615A1 (ru) 2009-04-28
AU2007258896A1 (en) 2007-12-21
CR10459A (es) 2009-01-09
HN2008001788A (es) 2012-08-27
EP2032172A2 (en) 2009-03-11
KR20090018103A (ko) 2009-02-19
AU2007258896B2 (en) 2013-01-24
EP1864682A1 (en) 2007-12-12
SG174067A1 (en) 2011-09-29
MA30689B1 (fr) 2009-09-01
TNSN08463A1 (en) 2010-04-14
BRPI0712899A2 (pt) 2013-01-08
US20090182038A1 (en) 2009-07-16
NO20085127L (no) 2009-01-08
MX2008015728A (es) 2009-01-09
CN101466409B (zh) 2012-11-21

Similar Documents

Publication Publication Date Title
UA95959C2 (en) Leptomycin derivatives
WO2007112193A3 (en) Camptothecin-binding moiety conjugates
WO2009100194A3 (en) Camptothecin-binding moiety conjugates
MY157715A (en) Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use
WO2007038658A3 (en) Antibody-drug conjugates and methods of use
UA98153C2 (ru) Цитотоксическое средство, содержащее производные томаймицина, и его терапевтическое применение
EP2952210A3 (en) Compositions comprising saccharide binding moieties and methods for targeted therapy
NZ620174A (en) Protein kinase conjugates and inhibitors
EA201390642A1 (ru) Цитотоксические агенты, содержащие новые производные анзамитоцина
WO2008106186A3 (en) Activated polyoxazolines and compositions comprising the same
NZ588884A (en) Cross-linkers and their uses
EP4321177A3 (en) Carbohydrate conjugates as delivery agents for oligonucleotides
UA111341C2 (uk) Аматоксиновий кон'югат з покращеними лінкерами
WO2007105027A8 (en) Anticancer drugs conjugated to antibody via an enzyme cleavable linker
WO2010014913A8 (en) Toll-like receptor agonist formulations and their use
EA200800657A1 (ru) Способ приготовления очищенных конъюгатов лекарственных средств
IN2012DN03025A (ru)
IL188603A0 (en) Preparation of insulin conjugates
MX2010005683A (es) Conjugados de anticuerpos anti-rg-1.
WO2005086974A3 (en) Methods and compositions for treating cancer
WO2005002516A3 (en) Leukocyte internalized peptide-drug conjugates
MX2009009533A (es) Conjugados de hidroxipolimero modificado con efecto letal en celulas tumorales.
WO2010032248A3 (en) Multifunctional albumin conjugates
ZA202101990B (en) Sulfomaleimide-based linkers and corresponding conjugates
WO2007100904A3 (en) Conjugate for the specific targeting of anticancer agents to tumor cells or tumor vasculature and production thereof